Litigation Details for Vanda Pharmaceuticals Inc. v. Apotex Inc. (D. Del. 2021)

« Back to Dashboard

Vanda Pharmaceuticals Inc. v. Apotex Inc. (D. Del. 2021)

Docket		Date Filed	2021-02-24
Court	District Court, D. Delaware	Date Terminated	2022-12-14
Cause	35:1 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	10,610,510; 10,610,511; 10,829,465
Link to Docket	External link to docket

Details for Vanda Pharmaceuticals Inc. v. Apotex Inc. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-02-24				External link to document

Vanda Pharmaceuticals Inc. v. Apotex Inc. | 1:21-cv-00282 Litigation Summary and Patent Analysis

Last updated: September 3, 2026

Vanda Pharmaceuticals sued Apotex in the U.S. District Court for the District of Delaware after Apotex filed an abbreviated new drug application seeking approval for a generic version of Hetlioz, Vanda's tasimelteon product. The dispute concerned patent protection for tasimelteon used to treat Non-24-Hour Sleep-Wake Disorder. Vanda asserted Orange Book-listed method-of-use patents, triggering the Hatch-Waxman litigation process and an FDA approval stay.

The case was resolved through a settlement rather than a trial or merits judgment. The public record does not establish an immediate generic launch. The commercial effect was therefore a negotiated delay of Apotex's market entry, subject to the confidential terms of the settlement agreement. [1][2]

What drug and indication were involved in Vanda v. Apotex?

The litigation involved Hetlioz capsules, which contain tasimelteon, a melatonin-receptor agonist.

Item	Description
Brand	Hetlioz
Active ingredient	Tasimelteon
Sponsor	Vanda Pharmaceuticals Inc.
Dosage form	Oral capsules
FDA indication	Treatment of Non-24-Hour Sleep-Wake Disorder in totally blind individuals
Regulatory pathway for Apotex	ANDA
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:21-cv-00282
Filed	February 25, 2021
Litigation type	Hatch-Waxman patent infringement action

The FDA approved Hetlioz in 2014 for Non-24-Hour Sleep-Wake Disorder in totally blind individuals. The agency later approved Hetlioz LQ, an oral liquid formulation, for the same general disease area. The Apotex litigation concerned the generic product identified in Vanda's complaint as an ANDA product for Hetlioz capsules, not a biosimilar product. [3][4]

What patents did Vanda assert against Apotex?

Vanda's complaint identified patents covering the use of tasimelteon for circadian rhythm disorders and related treatment methods. The case was based on Orange Book patent certifications submitted in connection with Apotex's ANDA.

The principal patent family associated with the dispute included the following patents:

Patent	General subject matter	Relevance
U.S. Patent No. 8,586,610	Treatment of circadian rhythm disorders with tasimelteon	Core method-of-use protection
U.S. Patent No. 8,673,927	Tasimelteon treatment methods	Method-of-use protection
U.S. Patent No. 9,050,302	Treatment of Non-24-Hour Sleep-Wake Disorder	Indication-specific protection
U.S. Patent No. 9,566,220	Circadian rhythm treatment protocols	Follow-on method claims
U.S. Patent No. 10,149,829	Tasimelteon treatment methods	Later-issued Orange Book protection
U.S. Patent No. 10,610,548	Additional treatment and dosing claims	Later-issued patent protection

The asserted claims were method claims rather than basic composition-of-matter claims. That distinction matters. Method patents generally provide narrower protection than a valid compound patent because infringement depends on the proposed product's labeling, physician use, and the scope of the claimed treatment protocol.

The public case materials should be read together with the relevant Orange Book editions because the listed patent set can change as patents expire, are delisted, or are superseded by later listings. [1][5]

What was Apotex's Paragraph IV challenge?

Apotex's ANDA filing included Paragraph IV certifications challenging the validity, enforceability, or infringement of Vanda's listed patents. A Paragraph IV certification is an assertion that a listed patent is invalid, unenforceable, or will not be infringed by the ANDA product.

Vanda treated Apotex's certification and notice as an act of patent infringement under 35 U.S.C. § 271(e)(2). The complaint sought:

• A declaration that the asserted patents were valid and enforceable.
• A declaration that Apotex's proposed product would infringe.
• An injunction preventing commercial manufacture, use, offer for sale, sale, or importation before patent expiration.
• A prohibition on FDA approval of the ANDA before the statutory patent protection period ended.
• Costs, interest, and other relief available under the Patent Act.

The case did not produce a public trial verdict determining whether the asserted claims were valid or infringed. The settlement eliminated the need for a final adjudication.

When did the FDA approval stay apply?

Under the Hatch-Waxman statute, a timely patent-infringement action based on a Paragraph IV certification generally imposes a 30-month stay on FDA approval of the ANDA, unless the court orders otherwise or the litigation ends earlier.

Vanda's filing occurred within the statutory notice period. The litigation therefore preserved the 30-month stay associated with the challenged patents. The stay blocked FDA approval during the statutory period, subject to earlier termination through settlement, dismissal, or another court order.

The stay did not itself establish patent validity. It was a regulatory consequence of the Paragraph IV litigation process.

How was Vanda v. Apotex resolved?

The parties resolved the action by settlement and the case was terminated without a merits judgment. The settlement terms were not fully disclosed in the public docket.

The public record does not provide a judicial finding that:

• The asserted patents were valid.
• The asserted patents were infringed.
• Apotex's ANDA product would infringe.
• Apotex's ANDA was approved by the FDA.
• Apotex launched a generic product.

The absence of a merits decision limits the precedential value of the case. It also leaves the validity and claim-construction risks associated with the asserted patents unresolved for later challengers.

For commercial purposes, the most important settlement issue is the agreed launch date or launch conditions. Because those terms were confidential, the docket does not provide a complete public answer on the earliest permitted Apotex launch date. Settlement agreements in Hatch-Waxman cases can include an agreed entry date, a license, manufacturing restrictions, supply terms, or provisions tied to other generic entrants.

What is the Orange Book status of Hetlioz?

Hetlioz's commercial protection has relied on a layered Orange Book estate rather than a single patent.

Method-of-use patents

The principal protection covers the administration of tasimelteon to patients with Non-24-Hour Sleep-Wake Disorder and related circadian rhythm disorders. These patents can support Paragraph IV litigation even when the generic sponsor seeks approval for the same active ingredient and dosage form.

Formulation protection

Hetlioz capsule patents protect the finished dosage form and related pharmaceutical composition concepts where listed. The Apotex case was principally associated with the capsule product and method-of-use claims. Hetlioz LQ represents a separate oral-liquid product and may have separate formulation and regulatory protection.

Regulatory exclusivity

Hetlioz received FDA approval for an orphan disease indication. Orphan-drug exclusivity generally provides seven years of protection against approval of the same drug for the same indication, subject to statutory exceptions. Orphan exclusivity is separate from patent rights and does not prevent all forms of generic or competing approval.

The principal long-term barrier in this dispute was patent protection, not orphan exclusivity. [3][4]

How strong was Vanda's patent estate?

Vanda's estate had meaningful commercial value but presented litigation vulnerabilities.

Strengths

The estate had several patents covering the same therapeutic field. Layered method claims can delay generic approval even when a challenger defeats one patent.

The patents were directed to a defined patient population and a specific disorder. Such claims can be commercially important where the generic label is expected to track the reference product's FDA-approved indication.

The patents were listed in the Orange Book, allowing Vanda to invoke the statutory approval stay and obtain a judicial forum before generic approval.

Weaknesses

Method-of-use patents face potential invalidity attacks based on anticipation, obviousness, written description, enablement, and claim construction.

The Federal Circuit has scrutinized Vanda's tasimelteon patent estate in other litigation. In Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., the Federal Circuit addressed obviousness arguments involving tasimelteon treatment claims. That decision did not automatically determine the outcome of the Apotex case, but it shows the technical and legal issues likely to arise in challenges to Vanda's patents. [6]

The estate also had aging patents with different priority dates and expiration dates. A generic company can target the earliest commercially useful entry opportunity rather than challenge every patent in the portfolio.

What generic entry risks existed for Hetlioz?

The Apotex action created several possible entry scenarios.

Scenario	Commercial effect
Settlement with delayed entry	Protects a defined period of branded sales while avoiding trial risk
Early licensed entry	Allows Apotex to launch before the full patent term under agreed conditions
Successful Paragraph IV defense	Could permit launch before patent expiration
Vanda trial victory	Could block approval until patent expiration or settlement modification
Failure of one patent	May not produce entry if other listed patents remain enforceable
At-risk launch	Could expose Apotex to damages and injunctive relief

The case's settlement posture reduced the probability of an immediate at-risk launch. It did not eliminate future generic risk because other ANDA filers could challenge the same patents, and later patent expirations could permit entry independent of Apotex's agreement.

Which companies challenged or competed with Hetlioz?

The relevant competitive group included:

• Apotex, as the defendant in this action.
• Teva Pharmaceuticals, which separately litigated Vanda's tasimelteon patents.
• Other ANDA sponsors that may rely on Paragraph IV, Paragraph III, or section viii certifications.
• Competing products for circadian rhythm disorders, including melatonin-related therapies and off-label alternatives.

Hetlioz has a narrower approved indication than many sleep products. That limits direct substitution but increases the importance of label-based patent enforcement. A generic with an indication-matched label would present a greater infringement risk than a product using a legally permissible carve-out.

What revenue was exposed by the litigation?

Hetlioz has been a material product for Vanda. Vanda's annual reports identify Hetlioz as one of the company's primary commercial products, alongside Fanapt. The financial impact of generic entry would depend on:

• The number of approved ANDA competitors.
• The agreed Apotex entry date.
• Whether launch occurred with a full or carved-out indication.
• Generic price discounting.
• Pharmacy substitution and payer coverage.
• Patient dependence on the approved Non-24 indication.
• The timing of Hetlioz LQ and other formulation competition.

The settlement protected Vanda from the immediate uncertainty of a trial but did not provide public visibility into the precise duration of the commercial protection period. [2]

How does this case compare with Vanda's other patent litigation?

Vanda's tasimelteon cases share a common structure: an ANDA sponsor challenges method-of-use patents, and Vanda relies on the Orange Book and the 30-month stay.

Issue	Vanda v. Apotex	Vanda v. Teva
Product	Hetlioz/tasimelteon	Hetlioz/tasimelteon
Legal pathway	Hatch-Waxman	Hatch-Waxman
Main dispute	Validity and infringement of method claims	Validity and infringement of method claims
Public merits ruling	No final merits judgment	Federal Circuit decision addressed patent issues
Resolution	Settlement	Appellate litigation
Precedential value	Limited	Greater, because of appellate treatment

The Apotex case is commercially important but provides less legal guidance because it ended without a public merits opinion.

Key Takeaways

• Vanda sued Apotex in Delaware over an ANDA for generic Hetlioz, or tasimelteon capsules.
• The asserted protection centered on Orange Book-listed method-of-use and related treatment patents.
• Apotex used Paragraph IV certifications, triggering Hatch-Waxman litigation and the 30-month FDA approval stay.
• The parties settled, and the case ended without a trial or judicial ruling on validity or infringement.
• The settlement terms, including any agreed generic launch date, were not fully disclosed publicly.
• The case did not involve a biosimilar pathway.
• Vanda's patent estate was layered but exposed to ordinary method-of-use patent risks, including obviousness and claim-construction challenges.
• Other ANDA challengers could create separate entry risk even after the Apotex settlement.

FAQs About Vanda Pharmaceuticals Inc. v. Apotex

What was Apotex's generic product in the Vanda litigation?

Apotex's ANDA product was a proposed generic version of Hetlioz capsules containing tasimelteon for Non-24-Hour Sleep-Wake Disorder.

Did Apotex win the Hetlioz patent case?

No public merits judgment awarded Apotex a victory. The action was resolved through settlement and terminated without a trial decision.

Did the case involve Hetlioz LQ?

The litigation was associated primarily with the capsule version of Hetlioz. Hetlioz LQ is a separate oral-liquid formulation with its own regulatory and patent considerations.

Can another generic company still challenge Hetlioz patents?

Yes. A settlement with one ANDA sponsor does not prevent a different sponsor from filing a separate ANDA challenge, subject to the status of the relevant patents, exclusivity, and FDA requirements.

What is the principal legal risk to Vanda's Hetlioz franchise?

The main risk is generic entry following a successful Paragraph IV challenge, settlement-based licensed entry, patent expiration, or a label design that avoids the claims while retaining commercially meaningful approval.

References

1. Vanda Pharmaceuticals Inc. v. Apotex Inc., No. 1:21-cv-00282, Complaint, U.S. District Court for the District of Delaware (Feb. 25, 2021).

2. Vanda Pharmaceuticals Inc., Annual Report on Form 10-K for the applicable reporting periods, SEC filings.

3. U.S. Food and Drug Administration. (2014). FDA approves Hetlioz to treat Non-24-hour sleep-wake disorder in totally blind individuals.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book listings for Hetlioz.

5. United States Patent and Trademark Office. (n.d.). Patent Center records for U.S. Patent Nos. 8,586,610; 8,673,927; 9,050,302; 9,566,220; 10,149,829; and 10,610,548.

6. Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., 57 F.4th 141 (Fed. Cir. 2023).